IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Our understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still developing. We perform an observational study to investigate seroprevalence and immune responses in subjects professionally exposed to SARS-CoV-2 and their family members (155 individuals; ages 5–79 years). Seropositivity for SARS-CoV-2 Spike glycoprotein aligns with PCR results that confirm the previous infection. Anti-Spike IgG/IgM titers remain high 60 days post-infection and do not strongly associate with symptoms, except for fever. We analyze PBMCs from a subset of seropositive and seronegative adults. TLR7 agonist-activation reveals an increased population of IL-6 + TNF - IL-1β + monocytes, while SARS-CoV-2 peptide stimulation elicits IL-33, IL-6, IFNa2, and IL-23 expression in seropositive individuals. IL-33 correlates with CD4 + T cell activation in PBMCs from convalescent subjects and is likely due to T cell-mediated effects on IL-33-producing cells. IL-33 is associated with pulmonary infection and chronic diseases like asthma and COPD, but its role in COVID-19 is unknown. Analysis of published scRNAseq data of bronchoalveolar lavage fluid (BALF) from patients with mild to severe COVID-19 reveals a population of IL-33-producing cells that increases with the disease. Together these findings show that IL-33 production is linked to SARS-CoV-2 infection and warrant further investigation of IL-33 in COVID-19 pathogenesis and immunity.
Article activity feed
-
-
SciScore for 10.1101/2020.07.09.20148056: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Human subjects: All procedures involving human subjects were approved by the Ethics Committee of the Medical Center - University of Freiburg (305/20).
Consent: Inclusion criteria were contact to SARS-CoV-2-infected individuals, age of at least 5 years and the ability to provide a written informed consent.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable This cohort included 50% males (n=8) and 50% females. Table 2: Resources
Antibodies Sentences Resources Plates were washed four times with PBS/T and incubated with an anti-human IgG or IgM secondary antibody (dilution 1:3000, Sigma or Thermo Fisher Scientific) … SciScore for 10.1101/2020.07.09.20148056: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Human subjects: All procedures involving human subjects were approved by the Ethics Committee of the Medical Center - University of Freiburg (305/20).
Consent: Inclusion criteria were contact to SARS-CoV-2-infected individuals, age of at least 5 years and the ability to provide a written informed consent.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable This cohort included 50% males (n=8) and 50% females. Table 2: Resources
Antibodies Sentences Resources Plates were washed four times with PBS/T and incubated with an anti-human IgG or IgM secondary antibody (dilution 1:3000, Sigma or Thermo Fisher Scientific) for 1 h at room temperature. anti-human IgGsuggested: NoneIgMsuggested: (Thermo Fisher Scientific Cat# MA1-4803, RRID:AB_612248)Software and Algorithms Sentences Resources Data analysis and Statistics: Flow cytometry data were analyzed using FlowJo version 10.6. FlowJosuggested: (FlowJo, RRID:SCR_008520)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 32. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
